|
summary: The authors report the findings of the phase II clinical trial of laquinimod, a new oral medication for relapsing-remitting MS. They found that the treatment was safe and that it reduced MRI activity over 36 weeks of treatment. This is encouraging and the next step is a phase III trial looking at clinical effects in larger groups of patients.
authors: Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5062 Study Group.
source: Lancet. 2008 Jun 21;371(9630):2085-92.
weblink: click here
category: Clinical Trials and Therapeutics
related research news: click here
glossary:
ACE
Clinical trial
Computerized
Magnetic Resonance Imaging (MRI)
Multiple sclerosis
Placebo
Randomised
Relapsing/remitting MS
Sclerosis
|
